Baum et al. [12] have performed the first in-human study on peptide-targeted radionuclide therapy using 177Lu-FAP-2286 to treat 68Ga-FAP-2286- or [68Ga]Ga-FAPI-04-positive liver metastases from breast, pancreas, rectum, or ovary adenocarcinomas, reporting high 177Lu-FAP-2286 uptake in tumor lesions up to 10 days after treatment (3.0 ± 2.7 Gy/GBq), yet no Grade 4 adverse events (most patients complained of self-limiting headaches, temporary flare-up of the abdominal pain, anemia, or pancytopenia). Here, FAP is linked to neoplasm.